Hepatitis B virus (HBV) is a hepatotropic virus that can establish a persistent and chronic
infection in humans through immune anergy. Currently, 3.5% of the global population is …

Our understanding of the natural history of hepatitis B virus (HBV) infection and the potential
for therapy of the resultant disease has improved. Several new and effective antiviral agents …

Our understanding of the natural history of hepatitis B virus (HBV) infection and the potential
for therapy of the resultant disease is continuously improving. New data have become …

Since the introduction of the hepatitis B vaccine and other preventive measures, the
worldwide prevalence of hepatitis B infection has fallen. However, chronic infection remains …

Large amounts of new data on the natural history and treatment of chronic hepatitis B virus
(HBV) infection have become available since 2005. These include long-term follow-up …

Quantitative HBsAg had been suggested to be helpful in management of HBV, but assays
were cumbersome. The recent availability of commercial quantitative assays has restarted …

Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …

Chronic HBV infection is an important public health problem worldwide and in the United
States. A treatment algorithm for the management of this disease, published previously by a …

Pegylated interferon alfa‐2a (PEG‐IFN) may induce sustained virological response (SVR) in
20% of hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B (CHB) patients. In …

Chronic hepatitis B virus (HBV) infection remains a major health burden worldwide for which
there is still no effective curative treatment. Interferon (IFN) consists of a group of cytokines …